Cell therapy technology is becoming the most active field of frontier medicine and may become a powerful weapon to fight against tumor. Regenerative medicine helps more and more people who suffer from hearing loss. Where are the opportunities behind these buzzwords? What’s the future of cell therapeutics? In the healthcare panel, we invite leaders from academia, pharma, biotech to share their expertise and insights on the gene therapy of the future.
2019 HIGHLIGHT SPEAKERS
Robert Deans, Ph.D. is the Chief Innovation Officer in Bayer-BlueRock Therapeutics. He joined BlueRock in 2017 and is responsible for building BlueRock’s novel CELL+GENE platform. He has more than 25 years of experience in cell therapeutics. His research has resulted in the successful clinical development of 4 therapeutic cell platforms and 8 INDs in late-stage development. Dr. Deans previously served as CSO of Rubius Therapeutics, where he was responsible for development of a gene-engineered red cell therapeutics platform. He holds a B.S. from the Massachusetts Institute of Technology and a Ph.D. in microbiology from the University of Michigan.
Loïc Vincent, Ph.D. is the Vice President of Takeda Pharmaceutical, mainly focus on Immuno-Oncology & Cell Therapy Discovery. He is a member of Takeda’s Immuno-Oncology Drug Discovery Unit and Takeda’s Cell Therapy Leadership Teams based at Takeda’s Cambridge, MA, research campus. Prior to joining Takeda in 2016, Dr. Vincent spent 9 years at Sanofi, where he led Oncology Drug Discovery Pharmacology, Immunotherapy and Oncology External Innovation teams. Dr. Vincent obtained his PhD in Pharmacology from the University of Rouen, France. Dr. Vincent carried out his postdoctoral fellowship in Oncology at the Weill Medical College of Cornell University.
Dr. Chen is an Associate Professor of Otolaryngology in Harvard Medical School. He has a long-standing interest in the regenerative medicine of genetic hearing loss. One of the most important goals is to renew proliferation and hair cell regeneration in adult and aged mammalian inner ear. Dr. Chen has recently identified a mechanism by which adult and aged mammalian inner ear cells can re-enter cell cycle. This exciting work sets a stage to restore hearing in deaf animals and animals with noise-induced and age-related hearing loss. Dr. Chen obtained his PhD from the Oxford University.
Wei Zhao is the Executive Director of 6 Dimensions Capital. He joined WuXi Healthcare Ventures (now 6 Dimensions Capital) in 2016. He was a Senior Life Sciences Specialist at L.E.K. Consulting Boston office, and a postdoctoral fellow at Mass. Eye and Ear Infirmary and Harvard Medical School. Wei obtained his Ph.D. in Neuroscience from Northwestern University, and B.S. from Tsinghua University.